Qianben Wang

Duke University — United States

Medicine · Health Sciences

42h-index9.4kcitations156works5.62yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Prostate Cancer Treatment and Research(79), Estrogen and related hormone effects(32), Genomics and Chromatin Dynamics(23), Cancer, Lipids, and Metabolism(23), Cancer Genomics and Diagnostics(20)

Publications156 total

Single-dose cathepsin L CRISPR nanotherapy mitigates PASC-like lung damage in hamsters
Nano Research·2025Open Access
Emerging therapies to overcome antiandrogen resistance and beyond in lethal prostate cancer
Journal of the National Cancer Center·2025· 7 citedOpen Access
SCORT–Cas13d Nanotherapy Precisely Targets the ‘Undruggable’ Transcription Factor HoxB13 in Metastatic Prostate Cancer In Vivo
Advanced Science·2025· 2 citedOpen Access
Abstract 1625: Redox homeostasis is a therapeutic vulnerability in lethal neuroendocrine prostate cancer
Cancer Research·2025
Integrative analysis identifies the atypical repressor E2F8 as a targetable transcriptional activator driving lethal prostate cancer
Oncogene·2024· 3 cited
Integrated single-cell analysis reveals distinct epigenetic-regulated cancer cell states and a heterogeneity-guided core signature in tamoxifen-resistant breast cancer
Genome Medicine·2024· 19 citedOpen Access
Structural insights into the cooperative nucleosome recognition and chromatin opening by FOXA1 and GATA4
Molecular Cell·2024· 11 citedOpen Access
USP11 promotes prostate cancer progression by up-regulating AR and c-Myc activity
Proceedings of the National Academy of Sciences·2024· 20 citedOpen Access
Abstract 5359: Targeted engineering mRNA 3′UTR length enhances immunotherapy response in prostate cancer
Cancer Research·2024
Abstract 495: Targeting undruggable transcription factor HOXB13 in metastatic prostate cancer by CRISPR/Cas13d-based nanoparticle therapy
Cancer Research·2024
Abstract 948: A novel combinatorial therapy for lethal neuroendocrine prostate cancer
Cancer Research·2024
Hormone-induced enhancer assembly requires an optimal level of hormone receptor multivalent interactions
Molecular Cell·2023· 51 citedOpen Access
Deciphering and targeting host factors to counteract SARS-CoV-2 and coronavirus infections: insights from CRISPR approaches
Frontiers in Genome Editing·2023Open Access
Abstract 1454: SMAD3 promotes expression and activity of the androgen receptor in prostate cancer
Cancer Research·2023
Abstract 1723: Ferroptosis is a novel therapeutic target for RB1 deficient lethal prostate cancer
Cancer Research·2023
Supplementary Table S5 from Single-Cell RNA-seq Reveals a Subpopulation of Prostate Cancer Cells with Enhanced Cell-Cycle–Related Transcription and Attenuated Androgen Response
2023Open Access
Supplementary Table S5 from Single-Cell RNA-seq Reveals a Subpopulation of Prostate Cancer Cells with Enhanced Cell-Cycle–Related Transcription and Attenuated Androgen Response
2023Open Access
Supplementary Table S2 from Single-Cell RNA-seq Reveals a Subpopulation of Prostate Cancer Cells with Enhanced Cell-Cycle–Related Transcription and Attenuated Androgen Response
2023Open Access
Supplementary Table 1 from Shaping Chromatin States in Prostate Cancer by Pioneer Transcription Factors
2023Open Access
Supplementary Table S2 from Single-Cell RNA-seq Reveals a Subpopulation of Prostate Cancer Cells with Enhanced Cell-Cycle–Related Transcription and Attenuated Androgen Response
2023Open Access
page 1 of 8Next →

Frequent Co-authors

Zhong Chen(17), Myles Brown(14), Dayong Wu(14), Victor X. Jin(11), Tim H.‐M. Huang(8), Jiaoti Huang(8), Benjamin Sunkel(7), Steven K. Clinton(7), Jason S. Carroll(5), X. Shirley Liu(5), Wei Li(5), William Hankey(5), Kenneth P. Nephew(5), Clifford A. Meyer(4), Steven P. Balk(4), Jennifer M. Thomas‐Ahner(4), Pearlly S. Yan(4), Zhihua Liu(4), Chunpeng Zhang(4), Xun Lan(4)